PRECISION MEDICINE ACTION FOR CANCER
PMAC

OFFICIAL POLICY ON INDIRECT COSTS

Effective Date: January 9, 2026

Applicability: All Research Agreements, Clinical Trial Agreements, Grants, and Sub-awards

1. Purpose
As a non-profit consortium dedicated to advancing cancer research, PMAC aims to ensure that the highest possible percentage of funding is directed toward direct scientific investigation.

2. Indirect Cost Rate
PMAC has a strictly enforced global policy regarding indirect costs (Facilities & Administrative costs). We provide reimbursement for indirect costs at a rate not to exceed 10% of total direct costs (excluding equipment and sub-contracts over $50,000).

3. Policy Uniformity
This limit is a formal, non-negotiable policy of the organization and is applied consistently to all funding mechanisms—including basic, translational, and clinical research projects, prospective clinical trial agreements, grants, and sub-awards—regardless of the recipient institution's Federally Negotiated Indirect Cost Rate Agreement (NICRA) or standard clinical trial overhead rate.

4. Acceptance
Acceptance of funding from PMAC implies agreement with this indirect cost limitation.



Massimo Cristofanilli
President & CEO